AMGEN Inc AMGN Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$460.42 up $0.14, 0.03% at close Nov 6
Last close · Previous close $460.28
- Market cap
- At the Nov 6 close
- P/E ratio
- 26.69On last 12 months’ EPS
- Diluted EPS
- $17.25Last 12 months
- Dividend yield
- 2.16%Last 12 months
Price chart
$460.42up $0.14, 0.03%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$460.28Nov 5
- Volume2.51MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.83MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $312.39 to $483.99; now $460.42
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
AMGN beat the S&P 500 in all 7 periods.
| Period | AMGN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AMGN: up 14.4% S&P 500: down 5.6% | AMGN beat the S&P 500 by 20.0 percentage points Beat |
| 3M | AMGN: up 14.4% S&P 500: down 4.1% | AMGN beat the S&P 500 by 18.5 percentage points Beat |
| YTD | AMGN: up 43.5% S&P 500: up 8.7% | AMGN beat the S&P 500 by 34.8 percentage points Beat |
| 1Y | AMGN: up 49.9% S&P 500: up 10.9% | AMGN beat the S&P 500 by 39.0 percentage points Beat |
| Long term | ||
| 3Y | AMGN: up 84.6% S&P 500: up 75.0% +22.7% vs +20.5% a year | AMGN beat the S&P 500 by 9.6 percentage points Beat |
| 5Y | AMGN: up 151.7% S&P 500: up 67.8% +20.3% vs +10.9% a year | AMGN beat the S&P 500 by 83.9 percentage points Beat |
| 10Y | AMGN: up 357.9% S&P 500: up 313.1% +16.4% vs +15.2% a year | AMGN beat the S&P 500 by 44.8 percentage points Beat |
$10,000 invested in AMGN 10 years ago (Nov 4, 2016) would be worth about $45,795 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
AMGN beat the S&P 500 in 5 of 7 periods.
| Period | AMGN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AMGN: up 14.4% S&P 500: down 5.6% | AMGN beat the S&P 500 by 20.0 percentage points Beat |
| 3M | AMGN: up 13.7% S&P 500: down 4.3% | AMGN beat the S&P 500 by 18.0 percentage points Beat |
| YTD | AMGN: up 40.7% S&P 500: up 7.8% | AMGN beat the S&P 500 by 32.9 percentage points Beat |
| 1Y | AMGN: up 45.9% S&P 500: up 9.7% | AMGN beat the S&P 500 by 36.2 percentage points Beat |
| Long term | ||
| 3Y | AMGN: up 68.8% S&P 500: up 68.8% +19.1% vs +19.1% a year | AMGN matched the S&P 500 Even |
| 5Y | AMGN: up 115.4% S&P 500: up 56.9% +16.6% vs +9.4% a year | AMGN beat the S&P 500 by 58.5 percentage points Beat |
| 10Y | AMGN: up 240.0% S&P 500: up 252.6% +13.0% vs +13.4% a year | AMGN trailed the S&P 500 by 12.6 percentage points Trailed |
$10,000 invested in AMGN 10 years ago (Nov 4, 2016) would be worth about $34,004 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$478.48
Closing high on . Now 3.8% below that record.
Split-adjusted daily closes since Sep 7, 1984.
Stock splits
5
Latest: 2-for-1 on . One share bought before the first split is 48 shares today.
All 5 splits
- 2-for-1
- 2-for-1
- 2-for-1
- 3-for-1
- 2-for-1
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $38.90Bup 8.2%
- Net income
- $9.39Bup 34.1%
- Diluted EPS
- $17.25up 33.3%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $9.09B | $627.00M | $1.16 |
| Q1 FY25 (Mar 31, 2025) | $8.15B | $1.73B | $3.20 |
| Q2 FY25 (Jun 30, 2025) | $9.18B | $1.43B | $2.65 |
| Q3 FY25 (Sep 30, 2025) | $9.56B | $3.22B | $5.93 |
| Q4 FY25 (Dec 31, 2025) | $9.87B | $1.33B | $2.46 |
| Q1 FY26 (Mar 31, 2026) | $8.62B | $1.82B | $3.34 |
| Q2 FY26 (Jun 30, 2026) | $10.05B | $2.38B | $4.37 |
| Q3 FY26 (Sep 30, 2026) | $10.37B | $3.86B | $7.08 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $25.98B | $5.89B | $10.28 |
| FY22 (Dec 31, 2022) | $26.32B | $6.55B | $12.11 |
| FY23 (Dec 31, 2023) | $28.19B | $6.72B | $12.49 |
| FY24 (Dec 31, 2024) | $33.42B | $4.09B | $7.56 |
| FY25 (Dec 31, 2025) | $36.75B | $7.71B | $14.23 |
Margins
- Gross 70.9%
- Operating 32.4%
- Net 24.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $9.58BLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$12.04BLast 12 months
- Capital spending$2.45BLast 12 months
- 24.6%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $0.00Last 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$5.37BLast 12 months
- Total returned$5.37BLast 12 months
56% of free cash flow
Balance sheet
- $13.19BAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$54.01BAs of Sep 30, 2026
- Net debt$40.82BAs of Sep 30, 2026
- 1.48As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 3.76As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 8 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 85.6%Last 12 months
Over the last 12 months, AMGEN’s net income was 85.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return. ROE can run this high when equity is small, for example after years of large share buybacks.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 10.0%Last 12 months
Over the last 12 months, AMGEN’s net income was 10.0% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $4.00 |
| 2017 | $4.60 |
| 2018 | $5.28 |
| 2019 | $5.80 |
| 2020 | $6.40 |
| 2021 | $7.04 |
| 2022 | $7.76 |
| 2023 | $8.52 |
| 2024 | $9.00 |
| 2025 | $9.52 |
| 2026 (to date) | $7.56 |
Dividend details
- $9.94Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- Dividend yield2.16%Last 12 months
- $2.52Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- FrequencyQuarterly4 payments in the last 12 months
- up 8.3% a yearFull years 2020–2025
The compound annual growth rate of the full-year dividend per share from 2020 to 2025.
- 13 yearsThrough 2025
How many calendar years in a row the full-year amount has risen, through 2025.
- 57.6%Last 12 months
The share of earnings paid out as dividends over the last 12 months. Lower ratios leave more room to reinvest or raise the dividend.
Payout = Dividends per share ÷ Diluted EPS (both last 12 months)Payout ratio calculator
About AMGEN Inc
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions. Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ®, and it is also part of the Nasdaq-100 Index ®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
AMGN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
AMGN stock FAQ
What is AMGN stock’s price today?
AMGEN (AMGN) traded at $460.42 at the close on , up $0.14 (0.03%) from the previous close of $460.28. Over the past 52 weeks it has traded between $312.39 and $483.99.
If you invested $1,000 in AMGN 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in AMGN on would be worth about $4,579 at the close on , a total return of +357.9%. The same $1,000 would be worth $2,517 if invested five years ago, $1,499 if invested one year ago, $9,179 if invested 20 years ago, and $46,644 if invested 30 years ago. Past performance doesn’t predict future returns.
What is AMGN’s P/E ratio?
AMGN trades at 26.7 times its diluted earnings over the four quarters to ($17.25 per share), at the close. (How the P/E ratio works.)
How much revenue does AMGEN make?
AMGEN reported $38.9 billion of revenue over the four quarters to , up 8.2% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $10.4 billion, up 8.5% from a year earlier.
Is AMGEN profitable?
Yes. AMGEN earned $9.4 billion of net income over the four quarters to , a net margin of 24.1%, and its operating margin was 32.4% (what margins tell you).
What are AMGN’s earnings per share?
AMGN’s diluted earnings per share were $17.25 over the four quarters to , compared with $12.94 in the twelve months before. The latest quarter (Q3 FY26) brought $7.08 per share, against $5.93 a year earlier (how EPS works).
Does AMGN pay a dividend?
Yes. AMGEN pays a quarterly dividend. The most recent was $2.52 per share, with an ex-dividend date of . Over the last twelve months it paid $9.94 per share, a 2.16% yield at the close, and the full-year dividend has risen 13 years in a row (how dividend yield works).
Based on the last 12 months’ payments ($9.94 per share), and if the next 12 months match the last 12, 100 shares would receive about $994 over 12 months, and $1,000 over 12 months would take about 101 shares, roughly $46,502 at the close. Dividends can change.
What is AMGN’s 52-week high and low?
Over the past 52 weeks AMGN has traded as low as $312.39 and as high as $483.99. At $460.42 at the close on , it is 4.9% below that high and 47.4% above the low.
What is AMGN’s all-time high?
AMGN’s highest closing price was $478.48 on , adjusted for stock splits. At $460.42 at the close on , it is 3.8% below that record.
Has AMGN stock ever split?
Yes, five times: 2-for-1 on ; 3-for-1 on ; 2-for-1 on ; 2-for-1 on ; 2-for-1 on . One share bought before the first split would be 48 shares today.
How has AMGN stock performed?
Including dividends and measured to the close on , AMGN has returned +43.5% so far this year and +49.9% over the past year, and +151.7% over five years (+20.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is AMGEN in?
AMGEN is in the Healthcare sector and the Drug Manufacturers - General industry, and is headquartered in California, USA.
What exchange does AMGN trade on?
AMGEN trades on the Nasdaq under the ticker symbol AMGN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.